GlassScriptPhysician profile
Jacquelyn Rose Baker
NPI 1144713728
$6,028.34
in general payments reported to CMS, 2019-2025
32 companies · $1,458 in 2025
The $1,458 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $950 · 2022: $1,056 · 2023: $1,209 · 2024: $1,356 · 2025: $1,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,924 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,923.84 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,281.53 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $956.98 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $925.85 | 2021-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $811.12 | 2021-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $308.66 | 2023-2025 | |
| Ardelyx, INC. | $219.88 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $175.49 | 2022-2024 | |
| Celgene Corporation | $152.23 | 2021-2024 | Zeposia |
| Celltrion USA INC. | $118.46 | 2024-2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $114.60 | 2022-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $114.26 | 2021-2025 | Rebyota |
| Aimmune Therapeutics, INC. | $102.34 | 2024-2025 | Zenpep |
| Qol Medical, LLC | $92.35 | 2025 | Sucraid |
| Phathom Pharmaceuticals, INC. | $91.22 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $69.88 | 2023-2024 | Linzess |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $68.13 | 2022-2024 | Dificid |
| Janssen Scientific Affairs, LLC | $51.65 | 2022 | |
| Intercept Pharmaceuticals, INC. | $50.16 | 2023-2025 | Ocaliva |
| Evoke Pharma, INC. | $47.88 | 2024 | |
| Braintree Laboratories, INC. | $41.65 | 2022-2024 | Suflave, Sutab |
| Daiichi Sankyo INC. | $39.59 | 2021 | |
| Lilly USA, LLC | $38.47 | 2024 | Omvoh |
| Madrigal Pharmaceuticals | $18.81 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $18.23 | 2024 | Iqirvo |
| Redhill Biopharma INC. | $16.50 | 2021 | |
| Fresenius Kabi USA, LLC | $16.47 | 2023 | Idacio |
| Nestle Healthcare Nutrition INC. | $16.45 | 2023 | |
| Pfizer INC. | $16.40 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.15 | 2023 | Cyltezo |
| Intra-Sana Laboratories | $14.47 | 2022 | |
| Novo Nordisk INC | $12.40 | 2022 | |
| Echosens North America, INC. | $10.08 | 2024 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacquelyn Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.